How Do I Find Mesothelioma Treatment Near Me?
If you’ve been diagnosed with mesothelioma, you and your family may be wondering where you can get the best treatment. Fortunately, there are many cancer centers across the country with doctors who specialize in mesothelioma. These doctors can develop a custom treatment plan based on your individual needs and diagnosis.
Your treatment plan may include a combination of chemotherapy, surgery, and other therapies. You may also be able to access new treatments through clinical trials.
The first step to receiving the right treatment is to make an appointment with a mesothelioma specialist.
We can help you connect with local mesothelioma doctors regardless of where you live. Try our Free Doctor Match now.
Top States for Mesothelioma Treatment
From Moffitt Cancer Center in Tampa to UCLA Medical Center in Los Angeles, there are a number of mesothelioma treatment centers across the country that can provide patients with specialized cancer care.
Some of the best mesothelioma cancer centers are located in:
- California
- Florida
- Illinois
- Ohio
- Texas
If you or a loved one is researching mesothelioma cancer centers, try looking for hospitals that have been recognized by the National Cancer Institute (NCI). This indicates that the facility has met strict criteria for conducting advanced cancer research aimed at finding better ways to prevent, diagnose, and treat mesothelioma.
All of the states listed above are home to at least one NCI-designated cancer center.
Mesothelioma Treatment Options
Pursuing treatment at a mesothelioma center is critical to improving your overall prognosis and life expectancy.
Pleural mesothelioma patients who receive standard treatments have higher survival rates than patients who go untreated, according to a 2023 report published in the journal Cancer Medicine.
Standard mesothelioma treatment options include:
- Surgery: Malignant mesothelioma patients may be eligible for tumor-removing surgeries as well as minor outpatient procedures that can help relieve swelling, chest pain, and other painful symptoms.
- Chemotherapy: Powerful chemotherapy medications administered orally or intravenously target and kill mesothelioma cancer cells throughout the body.
- Radiation therapy: High-energy radiation is delivered directly to areas with mesothelioma tumors, destroying cancer cells while minimizing damage to healthy tissues.
Mesothelioma cancer centers also offer emerging treatments such as immunotherapy that are being tested in clinical trials and showing improvements in overall survival for some mesothelioma patients. Immunotherapy drugs work by activating the body’s immune response to target and destroy cancer cells.
A 2021 clinical trial led by researchers at MD Anderson Cancer Center found that 40% of peritoneal mesothelioma patients achieved complete or partial remission after being treated with the immunotherapy medications atezolizumab (TECENTRIQ®) and bevacizumab (Avastin®).
Make sure to ask your specialist which treatment options are best for your stage and type of mesothelioma. Download our Free Checklist of Questions to Ask Your Doctor before your next appointment so you leave with the answers you need.
Locate Mesothelioma Clinical Trials Near You
Clinical trials for mesothelioma are available in some states. Mesothelioma Hope maintains an up-to-date list of ongoing clinical trials categorized by location.
Use our search tool below to see if there are any active mesothelioma clinical trials in your area and get help enrolling.
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors
- Malignant Pleural Mesothelioma
- Biological: CTX131
- Research Site 1, Nashville, Tennessee
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Single-Arm, Open-Label, Phase I Trial to Assess the Safety of Genetically Engineered Autologous T Cells Targeting the Cell Surface Antigen Mesothelin With Cell-Intrinsic Checkpoint Inhibition in Patients With Mesothelioma
- Malignant Pleural Mesothelioma (MPM)
- Drug: cyclophosphamide
- Biological: CAR T cells
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers
- Mesothelioma
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- Drug: Fludarabine + Cyclophosphamide combination
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
- Mesothelioma
- Biological: LMB-100
- Drug: ipilimumab
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
MAGIC-AKI: Magnesium for the Prevention of Hyperthermic Intraoperative Cisplatin-Associated AKI
- Mesothelioma
- Drug: Magnesium sulfate
- Brigham and Women's Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults
- Recurrent Malignant Mesothelioma
- Refractory Malignant Mesothelioma
- Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
- Drug: Cyclophosphamide
- Drug: Etoposide
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
- Mesothelioma (MPM)
- Drug: IK-930
- Massachusetts General Hospital, Boston, Massachusetts
- Start Midwest, Grand Rapids, Michigan
- Memorial Sloan Kettering Cancer Center, New York, New York
- Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
- Sarah Cannon Research Institute, Nashville, Tennessee
- MD Anderson Cancer Center, Houston, Texas
- Next Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
- Mesothelioma
- Mesothelioma, Malignant
- Mesothelioma; Pleura
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Biological: gavo-cel
- Drug: fludarabine
- Drug: cyclophosphamide
- University of California, San Francisco, San Francisco, California
- University of Miami Sylvester Cancer Center, Miami, Florida
- University of Chicago Medical Center, Chicago, Illinois
- National Cancer Institute, Bethesda, Maryland
- Columbia University Medical Center, New York, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Duke University, Durham, North Carolina
- University of Pennsylvania, Philadelphia, Pennsylvania
- Sarah Cannon Research Institute, Nashville, Tennessee
- University of Texas MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
- Mesothelioma
- Drug: Nivolumab Injection
- Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine, Baltimore, Maryland
- Johns Hopkins University, Baltimore, Maryland
- University of Texas M.D. Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Staging Procedures to Diagnose Malignant Pleural Mesothelioma
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
- Mesothelioma
- Mesotheliomas Pleural
- Mesothelioma, Malignant
- Mesothelioma Peritoneum
- Biological: TC-510
- Drug: Fludarabine
- Drug: Cyclophosphamide
- National Cancer Institute, Bethesda, Maryland
- University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota
- Montefiore Einstein Cancer Center, Bronx, New York
- Sarah Cannon Research Institute, Nashville, Tennessee
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- BAP1 Gene Mutation
- Mesothelioma
- The Ohio State University Wexner Medical Center, Columbus, Ohio
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
- Peritoneal Carcinomatosis
- Peritoneal Mesothelioma
- Procedure: Heated Intraperitonial Chemotherapy
- Drug: Oxaliplatin
- Drug: 5-Fluorouracil
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
- Nsclc
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Drug: AMXT1501
- Drug: DFMO
- Mayo Clinic - Arizona, Phoenix, Arizona
- Mayo Clinic - Florida, Jacksonville, Florida
- Mayo Clinic - Minnesota, Rochester, Minnesota
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
- MD Anderson Cancer Center, Houston, Texas
- Fred Hutch Cancer Center - Seattle Cancer Care Alliance, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
- Lung Cancer
- Mesothelioma
- Diagnostic Test: Biomarker Testing (L)
- Drug: Systemic Treatment (T)
- Teton Cancer Institute, Idaho Falls, Idaho
- Oncology and Hematology of South Texas, Laredo, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene
- Mesothelioma
- Drug: VT3989
- University of Chicago Medical Center, Chicago, Illinois
- Massachusetts General Hospital, Boston, Massachusetts
- Dana-Farber Cancer Institute, Boston, Massachusetts
- MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Feasibility and Clinical Results of Implementation of ERAS® Guidelines for Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: an International Prospective Cohort Study
- Peritoneal Diseases
- Other: Pre-ERAS® phase (current clinical practice)
- University of Texas Southwestern Medical Center, Dallas, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- Non-small Cell Lung Cancer
- Mesothelioma
- Drug: SGN-BB228
- University of California at San Francisco, San Francisco, California
- Sarah Cannon Research Institute at HealthONE - Denver, Denver, Colorado
- NYU Langone Hospital, New York, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
- Drug: CAR.70/IL15-transduced CB-derived NK cells
- Drug: Fludarabine phosphate
- Drug: Cyclophosphamide
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing
- Non Small Cell Lung Cancer
- Mesothelioma
- Mesothelioma, Malignant
- Mesothelioma; Lung
- Banner Health, Gilbert, Arizona
- City of Hope, Duarte, California
- University of California San Diego, La Jolla, California
- Stanford University, Palo Alto, California
- UCLA Medical Center, Santa Monica, California
- Mayo Clinic Jacksonville, Jacksonville, Florida
- Moffitt Cancer Center, Tampa, Florida
- Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts
- Mayo Clinic Rochester, Rochester, Minnesota
- Washington University, Saint Louis, Missouri
- NYU Langone Medical Center, New York, New York
- MD Anderson Cancer Center, Houston, Texas
- Fred Hutchinson Cancer Center, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors
- Primary Peritoneal Carcinoma
- Non-small Cell Lung Cancer
- Mesothelioma
- Drug: PRO1184
- University of California Los Angeles Medical Center, Los Angeles, California
- University of California, San Diego; Moores Cancer Center, San Diego, California
- Providence Medical Foundation, Santa Rosa, California
- University of Kansas Medical Center (KUMC), Westwood, Kansas
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- Karmanos Cancer Institute, Detroit, Michigan
- University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee
- Mary Crowley Cancer Research, Dallas, Texas
- START Mountain Region, West Valley City, Utah
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
- Pleural Mesothelioma
- Drug: Pembrolizumab
- Drug: Cisplatin and Pemetrexed
- University of Chicago, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I Dose Escalation and Local Control Study of Pembrolizumab + Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Pembrolizumab
- Radiation: IMPRINT
- Memoral Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: HFB200301
- Mayo Clinic, Scottsdale, Arizona
- USC/Norris Comprehensive Cancer Center, Los Angeles, California
- Mayo Clinic, Jacksonville, Florida
- Mayo Clinic, Rochester, Minnesota
- Washington University School of Medicine, Saint Louis, Missouri
- The University of Texas, MD Anderson Cancer Center, Houston, Texas
- NEXT Virginia Cancer Specialists, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Malignant Pleural Mesothelioma
- Drug: INBRX-109
- HonorHealth Research Institute, Scottsdale, Arizona
- City of Hope, Duarte, California
- Valkyrie Clinical Trials, Los Angeles, California
- Sarcoma Oncology Center, Santa Monica, California
- University of Colorado Hospital, Aurora, Colorado
- Emory University - Winship Cancer Institute, Atlanta, Georgia
- The University of Chicago, Chicago, Illinois
- University of Michigan, Ann Arbor, Michigan
- START Midwest Michigan, PC, Grand Rapids, Michigan
- Haley Phelan, New York, New York
- Cleveland Clinic, Cleveland, Ohio
- University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
- UT MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
- NEXT Oncology - Virginia, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer (SCLC)
- Mesothelioma
- Biological: pembrolizumab
- Call for Information (Investigational Site 0202), Los Angeles, California
- Call for Information (Investigational Site 0017), Los Angeles, California
- Call for Information (Investigational Site 0010), Boston, Massachusetts
- Call for Information (Investigational Site 0008), New Brunswick, New Jersey
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
- Mesothelioma
- Mesothelioma Malignant
- Mesothelioma; Lung
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Mesothelioma; Omentum
- Other: No intervention
- ProgenaBiome, Ventura, California
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Nivolumab
- Drug: Pemetrexed
- Drug: Cisplatin or Carboplatin
- Memoiral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey
- Memorial Sloan Kettering Bergen, Montvale, New Jersey
- Memorial Sloan Kettering Commack, Commack, New York
- Memorial Sloan Kettering Westchester, Harrison, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Memorial Sloan Kettering Nassau, Uniondale, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study of Pembrolizumab Plus Cryoablation in Patients With Unresectable Mesotheliomas
- Lung Cancer
- Unresectable Mesothelioma
- Drug: Pembrolizumab
- Procedure: Image-guided cryoablation
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
- Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York
- Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: NGM707
- University of Southern California, Los Angeles, California
- Hoag Memorial Hospital Presbyterian, Newport Beach, California
- UCLA Medical Center, Santa Monica, California
- Georgetown University Medical Center, Washington, District of Columbia
- Florida Cancer Specialists - Sarasota - SCRI, Sarasota, Florida
- University of Maryland Greenebaum Cancer Center, Baltimore, Maryland
- Dana-Farber Cancer Institute, Boston, Massachusetts
- START Midwest, LLC, Grand Rapids, Michigan
- Nebraska Cancer Specialists, Omaha, Nebraska
- Prisma Health - Upstate, Greenville, South Carolina
- University of Texas Southwestern Medical Center, Dallas, Texas
- MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open-label, Dose Escalation and Expansion, Phase 1a/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
- Mesothelioma
- Non-small Cell Lung Cancer (NSCLC), Non-squamous
- Drug: TAK-500
- City of Hope, Duarte, California
- University of California San Diego, La Jolla, California
- University of Colorado - Anschutz Medical Campus - PPDS, Aurora, Colorado
- Sarah Cannon Research Institute, Denver, Colorado
- Dana Farber Cancer Institute, Boston, Massachusetts
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- START South Texas Accelerated Research Therapeutics, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
- Drug: ASTX295
- City of Hope Comprehensive Cancer Center Site#114, Duarte, California
- Cedars-Sinai Medical Center Site #105, Los Angeles, California
- Hoag Hospital Site#110, Newport Beach, California
- Holden Comprehensive Cancer Center Site#108, Iowa City, Iowa
- University of Michigan Rogel Cancer Center Site#109, Ann Arbor, Michigan
- Regions Cancer Center Site #115, Saint Paul, Minnesota
- Columbia University Irving Medical Center - Herbert Irving Pavilion Site#104, New York, New York
- University of Pennsylvania-Abramson Cancer Center Site#113, Philadelphia, Pennsylvania
- The University of Texas MD Anderson Cancer Center Site #102, Houston, Texas
- NEXT Oncology Site #101, San Antonio, Texas
- Virgnia Cancer Specialists Site #103, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: MRTX1719
- Mayo Clinic, Phoenix, Arizona
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado
- Mayo Clinic, Jacksonville, Florida
- Dana Farber Cancer Institute, Boston, Massachusetts
- Mayo Clinic, Rochester, Minnesota
- Memorial Sloan Kettering Cancer Center, New York, New York
- NorthShore Hematology Oncology Associates P.C New York Cancer and Blood Specialists, Port Jefferson Station, New York
- Sarah Cannon Research Institute, Nashville, Tennessee
- MD Anderson Cancer Center, Houston, Texas
- START Center for Cancer Care, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)
- Lung Cancer
- Mesothelioma
- Radiation: MR-guided Linac
- Brigham & Women's Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
- Mesotheliomas Pleural
- Drug: Pembrolizumab
- Procedure: Indocyanine Green (ICG) Image-Guided Surgery
- Drug: Cisplatin
- Drug: Pemetrexed
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
- Mesothelioma
- Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Durvalumab
- University of California San Diego, La Jolla, California
- University of Miami, Miami, Florida
- Moffitt Cancer Center, Tampa, Florida
- Emory University, Atlanta, Georgia
- University of Chicago, Chicago, Illinois
- NorthShore University Health System/Kellogg Cancer Center, Evanston, Illinois
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
- Massaschusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- University of Michigan, Ann Arbor, Michigan
- Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota
- Morristown Medical/Atlantic Health, Morristown, New Jersey
- Jersey Shore University Medical Center, Neptune, New Jersey
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
- Memorial Sloan Kettering, New York, New York
- University of Cincinnati, Cincinnati, Ohio
- Cleveland Clinic Foundation, Cleveland, Ohio
- The Ohio State University, Columbus, Ohio
- Penn State Cancer Institute, Hershey, Pennsylvania
- Abramson Cancer Cener at Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- Allegheny Cancer Center, Pittsburgh, Pennsylvania
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
- University of Texas Southwestern Medical Center, Dallas, Texas
- Baylor College of Medicine, Houston, Texas
- MD Anderson Cancer Center, Houston, Texas
- University of Virginia, Charlottesville, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Biological: Safety
- Icahn School of Medicine Mount Sinai, New York, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Light Dosimetry for Intraoperative Photodynamic Therapy (IO-PDT) With Porfimer Sodium (Photofrin) in Patients With Malignant Mesothelioma or Non-Small Cell Lung Cancer (NSCLC), or Other Malignancies With Pleural Disease - Phase I Study
- Malignant Mesothelioma
- Non-Small Cell Lung Carcinoma
- Pleural Disorder
- Device: Light Dosimetry for Intranoperative Therapy
- Procedure: Photodynamic Therapy
- Drug: Porfimer Sodium
- Roswell Park Cancer Institute, Buffalo, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Inpatient Hospice With Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated With an Adoptive Cellular Therapy
- Mesothelioma
- Lung Cancers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
SBRT With Immunotherapy for Mesothelioma
- Pleural Mesothelial Neoplasm
- Other: Immunotherapy
- Other: Quality-of-Life Assessment
- Radiation: Stereotactic Body Radiation Therapy
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
- Non-Small Cell Lung Cancer Squamous
- Non-Small Cell Lung Cancer Non-squamous
- Pleural Mesothelioma
- Drug: MDNA11 Monotherapy
- Drug: MDNA11 in combination with checkpoint inhibitor
- Providence Saint John's Health Center, Santa Monica, California
- Boca Raton Regional Hospital, Boca Raton, Florida
- Orlando Health Cancer Institute, Orlando, Florida
- Emory - Winship Cancer Institute, Atlanta, Georgia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
- Procedure: Cytoreductive surgery
- Drug: LMB-100
- Diagnostic Test: Immunohistochemical Assay for Mesothelin
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma
- Malignant Mesothelioma
- Drug: Brentuximab Vedotin
- Other: Laboratory Biomarker Analysis
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
- Advanced Lung Non-Small Cell Carcinoma
- Advanced Lung Small Cell Carcinoma
- Advanced Pleural Malignant Mesothelioma
- Stage III Lung Cancer AJCC v8
- Stage III Pleural Malignant Mesothelioma AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Pleural Malignant Mesothelioma AJCC v8
- Drug: Cisplatin
- Drug: Elimusertib
- University of California Davis Comprehensive Cancer Center, Sacramento, California
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
- National Institutes of Health Clinical Center, Bethesda, Maryland
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Feasibility of the LUM Imaging System for Detection of Peritoneal Surface Malignancies
- Peritoneal Metastases
- Combination Product: LUM Imaging System
- Massachusetts General Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
- Malignant Mesothelioma
- Non-small Cell Lung Cancers
- Drug: PRT3645
- Miami Cancer Institute, Miami, Florida
- Florida Cancer Specialists, Sarasota, Florida
- Winship Cancer Institute, Emory University, Atlanta, Georgia
- Cleveland Clinic, Cleveland, Ohio
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
- Tennessee Oncology, PLLC, Nashville, Tennessee
- South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas
- NEXT Virginia, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
- Pleural Effusion, Malignant
- Ascites, Malignant
- Mesothelioma
- xCures, Oakland, California
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
- Mesothelioma
- Drug: IAG933
- University of Chicago Medical Center, Chicago, Illinois
- Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts
- Cleveland Clinic Foundation, Cleveland, Ohio
- MD Anderson Cancer Center/University of Texas, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma
- Non Small Cell Lung Cancer
- Mesothelioma
- Drug: AG-01 Compound
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Utilizing Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) With Pleural Disease or Malignant Pleural Mesothelioma (MPM) - Phase I Study
- Pleural Disorder
- Drug: Porfimer Sodium
- Procedure: Video-Assisted Thoracic Surgery
- Drug: Photodynamic Therapy
- Device: Intraoperative PDT
- Roswell Park Cancer Institute, Buffalo, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Randomized Phase 2 Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium -Mediated Photodynamic Therapy for Patients With Epitheliod Malignant Pleural Mesothelioma
- Epitheliod Malignant Pleural Mesothelioma
- Radiation: Photodynamic Therapy
- Procedure: Radical Pleurectomy
- Radiation: Chemotherapy
- Drug: Photofrin 2.0 mg/kg
- Rosewell Park, Buffalo, New York
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients With Thoracic Malignancies
- Malignant Pleural Mesotheliomas NOS
- Lung Cancer NOS
- Thoracic Cancers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
- Drug: TNG908
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- Washington University, Saint Louis, Missouri
- Sarah Cannon Tennessee Oncology, Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
- Mesothelioma
- Peritoneal Mesothelioma
- Diagnostic Test: HR-MRI
- Diagnostic Test: Standard CT Imaging
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
- Pleural Biphasic Mesothelioma
- Pleural Epithelioid Mesothelioma
- Stage I Pleural Malignant Mesothelioma AJCC v8
- Stage IA Pleural Malignant Mesothelioma AJCC v8
- Stage IB Pleural Malignant Mesothelioma AJCC v8
- Stage II Pleural Malignant Mesothelioma AJCC v8
- Stage IIIA Pleural Malignant Mesothelioma AJCC v8
- Drug: Carboplatin
- Drug: Cisplatin
- Procedure: Decortication
- Drug: Pemetrexed
- Drug: Pemetrexed Disodium
- Procedure: Pleurectomy
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
- Moffitt Cancer Center-International Plaza, Tampa, Florida
- Moffitt Cancer Center - McKinley Campus, Tampa, Florida
- Moffitt Cancer Center, Tampa, Florida
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Brigham and Women's Hospital, Boston, Massachusetts
- Mayo Clinic in Rochester, Rochester, Minnesota
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey
- Memorial Sloan Kettering Bergen, Montvale, New Jersey
- Memorial Sloan Kettering Commack, Commack, New York
- Memorial Sloan Kettering Westchester, Harrison, New York
- Mount Sinai Hospital, New York, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Memorial Sloan Kettering Nassau, Uniondale, New York
- Cleveland Clinic Foundation, Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- MD Anderson in The Woodlands, Conroe, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
- M D Anderson Cancer Center, Houston, Texas
- MD Anderson West Houston, Houston, Texas
- MD Anderson League City, League City, Texas
- MD Anderson in Sugar Land, Sugar Land, Texas
- Swedish Medical Center-First Hill, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
- Mesothelioma
- Other: MPT Test
- Other: CLDN15/VIM Test
- Brigham and Women's Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
- Mesothelioma, Malignant
- Biological: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
- University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
- Mesothelioma
- Drug: Olaparib
- University of Chicago Medical Center, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
- Metastatic Cancer
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Mesothelioma
- Drug: CTX-471
- Ocala Oncology Center, Ocala, Florida
- Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida
- Massachusetts General Hospital, Boston, Massachusetts
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri
- Hackensack University Medical Center, Hackensack, New Jersey
- Mt Sinai, New York, New York
- Duke University School of Medicine, Durham, North Carolina
- Institute for Translational Oncology Research (ITOR), Greenville, South Carolina
- Mary Crowley Cancer Research, Dallas, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies
- Drug: KZR-261
- Cedars Sinai Medical Center, Los Angeles, California
- Moffitt Cancer Center, Tampa, Florida
- Winship Cancer Institute of Emory University, Atlanta, Georgia
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville, Nashville, Tennessee
- START (South Texas Accelerated Research Therapeutics), San Antonio, Texas
- Virginia Cancer Specialists (VCS), Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
- Drug: ENV-101 (taladegib)
- Research Site, Los Angeles, California
- Research Site, San Diego, California
- Research Site, Santa Rosa, California
- Research Site, Tampa, Florida
- Research Site, Zion, Illinois
- Research Site, Covington, Louisiana
- Research Site, Las Vegas, Nevada
- Research Site, New York, New York
- Research Site, Durham, North Carolina
- Research Site, Cincinnati, Ohio
- Research Site, Cleveland, Ohio
- Research Site, Columbus, Ohio
- Research Site, Pittsburgh, Pennsylvania
- Research Site, Nashville, Tennessee
- Research Site, Houston, Texas
- Research Site, Fredericksburg, Virginia
- Research Site, Lynchburg, Virginia
- Research Site, Madison, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Peritoneal Malignant Mesothelioma
- Biological: Atezolizumab
- Biological: Bevacizumab
- Procedure: Biospecimen Collection
- Drug: Carboplatin
- Procedure: Computed Tomography
- Procedure: Cytoreductive Surgery
- Drug: Hyperthermic Intraperitoneal Chemotherapy
- Drug: Pemetrexed
- Procedure: Positron Emission Tomography
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Carle at The Riverfront, Danville, Illinois
- Carle Physician Group-Effingham, Effingham, Illinois
- Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois
- Carle Cancer Center, Urbana, Illinois
- The Carle Foundation Hospital, Urbana, Illinois
- University of Kentucky/Markey Cancer Center, Lexington, Kentucky
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts
- Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
- Fairview Southdale Hospital, Edina, Minnesota
- Unity Hospital, Fridley, Minnesota
- Abbott-Northwestern Hospital, Minneapolis, Minnesota
- Mayo Clinic in Rochester, Rochester, Minnesota
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota
- Regions Hospital, Saint Paul, Minnesota
- United Hospital, Saint Paul, Minnesota
- Sanford Bismarck Medical Center, Bismarck, North Dakota
- Sanford Broadway Medical Center, Fargo, North Dakota
- Sanford Roger Maris Cancer Center, Fargo, North Dakota
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
- Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota
- M D Anderson Cancer Center, Houston, Texas
- Marshfield Medical Center-Marshfield, Marshfield, Wisconsin
- Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors
- Small-cell Lung Cancer
- Mesothelioma
- Drug: INCB099318
- Hackensack University Medical Center, Hackensack, New Jersey
- Prisma Health Cancer Institute Faris, Greenville, South Carolina
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
- Mesothelioma
- Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
- City of Hope National Medical Center, Duarte, California
- Memorial Cancer Institute at Memorial Healthcare Systems, Pembroke Pines, Florida
- Atlantic Health System, Morristown Medical Center, Morristown, New Jersey
- Weill Cornell Medicine, Cornell University, New York, New York
- Gabrail Cancer Center Research, Canton, Ohio
- Erlanger Health System (Hospital); University of Tennessee College of Medicine, Chattanooga, Chattanooga, Tennessee
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- Medical College of Wisconsin, Milwaukee, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy)
- Recurrent Malignant Mesothelioma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Malignant Mesothelioma
- Resectable Malignant Mesothelioma
- Resectable Sarcoma
- Drug: Cisplatin
- Procedure: Cytoreductive Surgery
- Drug: Doxorubicin
- Drug: Hyperthermic Intraperitoneal Chemotherapy
- Drug: Sodium Thiosulfate
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Non Small Cell Lung Cancer
- Mesothelioma
- Drug: NGM438
- Yale Cancer Center, New Haven, Connecticut
- Henry Ford Health System, Detroit, Michigan
- START Midwest, Grand Rapids, Michigan
- Mount Sinai Hospital, New York, New York
- MD Anderson, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors
- Drug: IDE397
- Honor Health Research Institute, Scottsdale, Arizona
- City of Hope, Duarte, California
- Indiana University Health Hospital, Indianapolis, Indiana
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
- Dana Farber Cancer Institute, Boston, Massachusetts
- Columbia University Medical Center - Herbert Irving Pavilion, New York, New York
- Weill Cornell Medical College, New York, New York
- Stephenson Cancer Center, Oklahoma City, Oklahoma
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee
- MD Anderson, Houston, Texas
- Next Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
- Peritoneal Mesothelioma
- Pleural Mesothelioma
- Small Cell Lung Cancer
- Drug: XmAb20717
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
- Lung Adenocarcinoma
- Peritoneal Carcinoma
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Biological: huCART-meso cells
- University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies
- Mesothelioma
- Drug: APG-5918
- Highlands Oncology, Springdale, Arkansas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
- Soft Tissue Sarcoma (Excluding GIST)
- Mesothelioma
- Drug: Lurbinectedin
- Drug: Irinotecan
- Massachusetts General Hospital -, Boston, Massachusetts
- Beth Israel Deaconess Medical Center, Boston, Massachusetts
- The University of Texas MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Non-small Cell Lung Cancer
- Mesothelioma
- Drug: NGM831
- NGM Clinical Study Site, Gilbert, Arizona
- NGM Clinical Study Site, Los Angeles, California
- NGM Clinical Study Site, Sarasota, Florida
- NGM Clinical Study Site, Tampa, Florida
- NGM Clinical Study Site, Grand Rapids, Michigan
- NGM Clinical Study Site, New York, New York
- NGM Clinical Study Site, Oklahoma City, Oklahoma
- NGM Clinical Study Site, Austin, Texas
- NGM Clinical Study Site, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
- Mesothelioma, Malignant
- Drug: CPI-0209
- Emory University Hospital, Atlanta, Georgia
- University of Chicago Medical Center, Chicago, Illinois
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- University of Michigan, Ann Arbor, Michigan
- START Midwest, Grand Rapids, Michigan
- Hackensack University Medical Center, Hackensack, New Jersey
- Montefiore Einstein Center for Cancer Care, Bronx, New York
- NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center, New York, New York
- University of Cincinnati Medical Center, Cincinnati, Ohio
- START San Antonio, San Antonio, Texas
- University of Virginia Cancer Center, Charlottesville, Virginia
- Swedish Cancer Institute, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Integrated Cancer Repository for Cancer Research
- Lung Cancer
- Peritoneal Surface Malignancies
- Mesothelioma
- Penrose Cancer Center, Colorado Springs, Colorado
- Porter Adventist Hospital, Denver, Colorado
- Mercy Regional Medical Center, Durango, Colorado
- St. Anthony Hospital, Lakewood, Colorado
- Littleton Cancer Center, Littleton, Colorado
- Longmont Cancer Center, Longmont, Colorado
- Avista Cancer Center, Louisville, Colorado
- Parker Adventist Hospital, Parker, Colorado
- St. Mary Corwin Medical Center, Pueblo, Colorado
- St. Anthony North Cancer Center, Westminster, Colorado
- Florida Hospital Memorial Medical Center, Daytona Beach, Florida
- Florida Hospital DeLand, DeLand, Florida
- Florida Hospital FISH, Orange City, Florida
- Florida Hospital Flagler, Palm Coast, Florida
- Tallahassee Memorial Hospital, Tallahassee, Florida
- Rush-Copley Cancer Care Center, Aurora, Illinois
- Trinity Medical Center, Moline, Illinois
- Rush-Copley Healthcare Center, Yorkville, Illinois
- Parkview Research Center, Fort Wayne, Indiana
- Community Health Network, Indianapolis, Indiana
- Community Cancer Center South, Indianapolis, Indiana
- Community Cancer Center North, Indianapolis, Indiana
- Community Howard Regional Hospital, Kokomo, Indiana
- Methodist Jennie Edmundson Hospital, Council Bluffs, Iowa
- Genesis Medical Center, Davenport, Iowa
- Abben Cancer Center, Spencer, Iowa
- Covenant Medical Center, Inc, Waterloo, Iowa
- Saint Luke's Cancer Instititue - South, Overland Park, Kansas
- Tulane University, New Orleans, Louisiana
- Breast Care Specialists of Maine, Portland, Maine
- Northwest Hospital, Randallstown, Maryland
- William E Kahlert Regional Cancer Center, Westminster, Maryland
- Holyoke Medical Center, Holyoke, Massachusetts
- University of Michigan Health System, Ann Arbor, Michigan
- Riverwood Healthcare Center, Aitkin, Minnesota
- Essentia Health-St. Joseph's Medical Center, Brainerd, Minnesota
- Essentia Health - Duluth Clinic, Duluth, Minnesota
- St. Luke's Hospital of Duluth, Duluth, Minnesota
- Lake Region Healthcare, Fergus Falls, Minnesota
- Avera Cancer Institute- Marshall, Marshall, Minnesota
- Mercy Hospital - Joplin, Joplin, Missouri
- Saint Luke's Cancer Institute - East, Kansas City, Missouri
- Saint Luke's Cancer Institute, Kansas City, Missouri
- Saint Luke's Cancer Institute - Kansas City North, Kansas City, Missouri
- Saint Luke's Cancer Institute - Liberty, Liberty, Missouri
- Heartland Regional Medical Center dba Mosaic Life Care, Saint Joseph, Missouri
- Bozeman Health Deaconess Hospital, Bozeman, Montana
- Logan Health, Kalispell, Montana
- Providence St. Patrick Hospital Montana Cancer Center, Missoula, Montana
- Mary Lanning Healthcare/Morrison Cancer Center, Hastings, Nebraska
- Faith Regional Health Services, Carson Cancer Center, Norfolk, Nebraska
- Great Plains Regional Medical Center, North Platte, Nebraska
- Avera St. Anthony's Hospital, O'Neill, Nebraska
- Methodist Estabrook Cancer Center, Omaha, Nebraska
- Nebraska Methodist Health System, Omaha, Nebraska
- University of Nebraska Medical Center, Omaha, Nebraska
- Regional West Health Services, Scottsbluff, Nebraska
- C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls, New York
- Faxton St. Luke's Healthcare/Mohawk Valley, Utica, New York
- Cape Fear Valley Health System, Fayetteville, North Carolina
- Essentia Health, Fargo, North Dakota
- Trinity Hospital Cancer Care Center, Minot, North Dakota
- Aultman Alliance Community Hospital, Alliance, Ohio
- Aultman Hospital, Canton, Ohio
- University of Pittsburgh, Pittsburgh, Pennsylvania
- Avera Medical Group Oncology and Hematology Aberdeen, Aberdeen, South Dakota
- Avera Cancer Institute, Mitchell, South Dakota
- Avera Cancer Institute, Sioux Falls, South Dakota
- Sanford Health, Sioux Falls, South Dakota
- Avera Cancer Center Yankton, Yankton, South Dakota
- Avera Sacred Heart Hospital, Yankton, South Dakota
- Yankton Medical Clinic, Yankton, South Dakota
- Rutland Regional Medical Center, Rutland, Vermont
- Mary Washington Hospital, Fredericksburg, Virginia
- Ascension St. Elizabeth Hospital, Appleton, Wisconsin
- Wheaton Franciscan Healthcare - Elmbrook Memorial Hospital, Brookfield, Wisconsin
- Wheaton Franciscan Healthcare - Reiman Cancer Care, Franklin, Wisconsin
- Bellin Memorial Hospital, Green Bay, Wisconsin
- Columbia St. Mary's, Mequon, Wisconsin
- Columbia St. Mary's, Milwaukee, Wisconsin
- Ascension Mercy Hospital, Oshkosh, Wisconsin
- Wheaton Franciscan Healthcare - All Saints, Racine, Wisconsin
- Wheaton Franciscan Healthcare - Wauwatosa Cancer Care, Wauwatosa, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
- Small-cell Lung Cancer
- Mesothelioma
- Drug: INCB099280
- Dana Farber Cancer Institute, Boston, Massachusetts
- Henry Ford Hospital, Detroit, Michigan
- Upmc Cancercenter, Pittsburgh, Pennsylvania
- Md Anderson Cancer Center, Houston, Texas
- University of Washington, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination With Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies
- Metastatic Cancer
- Drug: Sym024
- START Midwest, Grand Rapids, Michigan
- MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
- Malignant Pleural Mesothelioma (MPM)
- Drug: NX-1607
- City of Hope, Duarte, California
- University of North Carolina, Chapel Hill, North Carolina
- MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Mesothelioma
- Drug: SO-C101
- Yale Cancer Center, New Haven, Connecticut
- University of Pittsburgh, Pittsburgh, Pennsylvania
- MD Anderson Cancer Center, Houston, Texas
What State Has the Most Mesothelioma Cases?
California ranks first among states with the most mesothelioma cases. A total of 6,503 Californians were diagnosed with mesothelioma between 1999 and 2018, according to the Centers for Disease Control and Prevention (CDC).
Mesothelioma Rates by State
Some states have higher rates of mesothelioma because they have a long history of industries that heavily relied on asbestos, such as shipbuilding, mining, and manufacturing.
According to CDC data, these 10 states have the highest incidence rates for mesothelioma:
| State | Mesothelioma Cases | Population | Incidence Rate |
|---|---|---|---|
| 1. Maine | 513 | 26,350,690 | 1.5% |
| 2. Alaska | 128 | 13,839,016 | 1.4% |
| 3. New Jersey | 2,654 | 174,234,048 | 1.4% |
| 4. Delaware | 272 | 17,554,499 | 1.4% |
| 5. Washington | 1,799 | 132,284,023 | 1.3% |
| 6. Louisiana | 1,228 | 90,660,676 | 1.3% |
| 7. West Virginia | 614 | 36,590,172 | 1.3% |
| 8. Wyoming | 147 | 10,870,011 | 1.3% |
| 9. Pennsylvania | 4,040 | 251,711,617 | 1.3% |
| 10. Wisconsin | 1,581 | 112,331,909 | 1.3% |
Thankfully, there are experienced specialists in each of these states who can treat people diagnosed with mesothelioma and other asbestos-related diseases.
Learn more about treatments, specialists, and help for asbestos exposure in our Free Mesothelioma Guide — shipped overnight to your door.
Find Mesothelioma Treatment Near You Today
Locating mesothelioma treatment near you is a crucial step you can take toward fighting this rare cancer. With advancements in mesothelioma research and treatment options, there is increasing hope for better survival outcomes and improved quality of life.
Our highly trained Patient Advocates can help you connect with mesothelioma doctors and treatment centers in your state. We can also see if you qualify for financial assistance that can help pay for your cancer treatments.
Find a mesothelioma specialist in your state to get started.
